Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0017636
Disease: Glioblastoma
Glioblastoma
0.400 Biomarker disease BEFREE MET Inhibition Elicits PGC1α-Dependent Metabolic Reprogramming in Glioblastoma. 31694905 2020
CUI: C0017636
Disease: Glioblastoma
Glioblastoma
0.400 Biomarker disease BEFREE Therefore, TBMS1 is a promising compound for the treatment of glioblastoma and an inhibitor of MET. 31349699 2019
CUI: C0017636
Disease: Glioblastoma
Glioblastoma
0.400 Biomarker disease BEFREE Our studies reveal a novel mechanism to alter the recycling process of MET in glioblastoma cancer cells by promoting the receptor degradation through a proteasome-sensitive and lysosome-dependent pathway through the ligand-independent activation of MET using anti-MET antibodies. 30760737 2019
CUI: C0017636
Disease: Glioblastoma
Glioblastoma
0.400 AlteredExpression disease BEFREE Our results indicated that the level of miR-562 was downregulated in GBM tissues and the expression of c-MET was upregulated in tumors. 30613151 2019
CUI: C0017636
Disease: Glioblastoma
Glioblastoma
0.400 Biomarker disease BEFREE Of the five target genes that were enriched in the glioblastoma pathway, in the WikiPathway database, both HRas proto-oncogene, GTPase and MET proto-oncogene, receptor tyrosine kinase target genes of hsa-miR-139-5p, were found to be significantly associated with patient survival. 31423264 2019
CUI: C0017636
Disease: Glioblastoma
Glioblastoma
0.400 Biomarker disease BEFREE MET and its ligand hepatocyte growth factor (HGF) play a critical role in the proliferation, survival, migration, invasion, angiogenesis, stem cell characteristics, and therapeutic resistance and recurrence of glioblastomas. 31221203 2019
CUI: C0017636
Disease: Glioblastoma
Glioblastoma
0.400 Biomarker disease BEFREE Intravenous administration of this formulation enhanced the curative efficacy of TMZ by downregulating the hepatocyte growth factor receptor (c-MET) gene in GBM U87 cells. 30982841 2019
CUI: C0017636
Disease: Glioblastoma
Glioblastoma
0.400 Biomarker disease BEFREE We identified critical proteins that were altered in MET inhibitor-resistant GBM including mTOR, FGFR1, EGFR, STAT3, and COX-2. 30201763 2019
CUI: C0017636
Disease: Glioblastoma
Glioblastoma
0.400 Biomarker disease BEFREE Finally, combined treatment with BH3-mimetics and c-MET inhibitors results in significantly smaller tumors than each treatment alone in a PDX model system of glioblastoma. 29743557 2018
CUI: C0017636
Disease: Glioblastoma
Glioblastoma
0.400 Biomarker disease BEFREE H1/pHGFK1 exerts anti-tumoural and radiosensitive activities mainly through the inhibition and reversal of IR-induced MET and ATM-Chk2 axis activities in glioblastoma. 29348487 2018
CUI: C0017636
Disease: Glioblastoma
Glioblastoma
0.400 Biomarker disease BEFREE Negative control of the HGF/c-MET pathway by TGF-β: a new look at the regulation of stemness in glioblastoma. 29238047 2017
CUI: C0017636
Disease: Glioblastoma
Glioblastoma
0.400 Biomarker disease BEFREE Previously, it was demonstrated that treatment with cabozantinib (MET/VEGFR2/RET inhibitor) prolonged survival of mice carrying orthotopic patient-derived xenografts (PDX) of the MET-addicted glioblastoma model E98, yet did not prevent development of recurrent and cabozantinib-resistant tumors. 28751462 2017
CUI: C0017636
Disease: Glioblastoma
Glioblastoma
0.400 AlteredExpression disease BEFREE GBM tissues frequently overexpressed MET protein at high levels compared with lower-grade gliomas. 28668888 2017
CUI: C0017636
Disease: Glioblastoma
Glioblastoma
0.400 Biomarker disease BEFREE Tumour exosomes from cells harbouring PTPRZ1-MET fusion contribute to a malignant phenotype and temozolomide chemoresistance in glioblastoma. 28504721 2017
CUI: C0017636
Disease: Glioblastoma
Glioblastoma
0.400 Biomarker disease BEFREE This study demonstrates the potential of integrated 11C-MET-PET/MRI for response assessment of GBM and the utility of combined assessment of morphologic and metabolic information with the proposal for assessing relapsed GBM. 28258444 2017
CUI: C0017636
Disease: Glioblastoma
Glioblastoma
0.400 Biomarker disease BEFREE In both cohorts, MET amplification was never detected in GBM devoid of strongly immunopositive cells. 26946354 2017
CUI: C0017636
Disease: Glioblastoma
Glioblastoma
0.400 Biomarker disease BEFREE In this study we investigated ALK, ROS1, and MET status in nine glioblastoma stem cell lines and tumors from which they arise. 28960893 2017
CUI: C0017636
Disease: Glioblastoma
Glioblastoma
0.400 GeneticVariation disease BEFREE This translational correlative component to the MET-PET clinical trials can lead to a better understanding of the existing controversies and can enhance our knowledge for future randomization of GBM patients based on their tumor gene signatures to achieve better prognosis and treatment outcome. 29164057 2017
CUI: C0017636
Disease: Glioblastoma
Glioblastoma
0.400 AlteredExpression disease BEFREE Recurrence of GB after chemo-radiation could be associated with a variation in PlGF and MET expression. 27566180 2016
CUI: C0017636
Disease: Glioblastoma
Glioblastoma
0.400 Biomarker disease BEFREE Recurrent MET fusion genes represent a drug target in pediatric glioblastoma. 27748748 2016
CUI: C0017636
Disease: Glioblastoma
Glioblastoma
0.400 Biomarker disease BEFREE Furthermore, we showed that PKCδ was aberrantly activated in GBM cells by c-MET, a receptor tyrosine kinase hyperactivated in GBM. 26700818 2016
CUI: C0017636
Disease: Glioblastoma
Glioblastoma
0.400 AlteredExpression disease BEFREE PV-O glioblastomas were associated with lower expression of VEGFC (p = 0.032) than other periventricular locations, whereas MET overexpression remained exceptional. 26637806 2016
CUI: C0017636
Disease: Glioblastoma
Glioblastoma
0.400 Biomarker disease BEFREE Our data provide new insights into the potential application of miR-144-3p in GBM therapy by targeting MET and then inhibiting the downstream signaling. 26250785 2015
CUI: C0017636
Disease: Glioblastoma
Glioblastoma
0.400 Biomarker disease BEFREE Genomic profiling of a Hepatocyte growth factor-dependent signature for MET-targeted therapy in glioblastoma. 26381735 2015
CUI: C0017636
Disease: Glioblastoma
Glioblastoma
0.400 Biomarker disease BEFREE We show that the RTKs MET, EGFR, and PDGFR regulate microRNA-134 (miR-134) in GBM. 24440911 2014